Journal of Antimicrobial Chemotherapy · 2018 · 32 citations · 21 references
PharmacyPharmacologyPharmacotherapyClinical PharmacologyInfectious Disease PharmacotherapyVirologyAntiretroviral TherapyAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyHuman Immunodeficiency Virus PharmacotherapyDrug DiscontinuationDual Therapy RegimensHighly Active Antiretroviral TherapyHiv Antiretroviral TherapyMaintenance Therapy TrialsNon-nucleoside Reverse Transcriptase InhibitorsOpen-label TrialsTreatment Discontinuation Rates
Objectives: To investigate the long-term safety and efficacy of a treatment switch to dual ART with atazanavir/ritonavir + lamivudine versus continuing a standard regimen with atazanavir/ritonavir + 2NRTI in virologically suppressed patients. Methods: ATLAS-M is a 96 week open-label, randomized, non-inferiority (margin -12%) trial enrolling HIV-infected adults on atazanavir/ritonavir + 2NRTI, with stable HIV-RNA <50 copies/mL and CD4 counts >200 cells/mm3. At baseline, patients were randomized 1:1 to switch to atazanavir/ritonavir + lamivudine or to continue the previous regimen. Here, we report the 96 week efficacy and safety data. The study was registered with ClinicalTrials.gov, number NCT01599364. Results: Overall, 266 subjects were enrolled (133 in each arm). At 96 weeks, in the ITT population, patients free of treatment failure totalled 103 (77.4%) with atazanavir/ritonavir + lamivudine and 87 (65.4%) with triple therapy (difference +12.0%, 95% CI +1.2/+22.8, P = 0.030), demonstrating the superiority of dual therapy. Two (1.5%) and 9 (6.8%) virological failures occurred in the dual-therapy arm and the triple-therapy arm, respectively, without development of resistance to any study drug. Clinical adverse events occurred at similar rates in both arms. A higher frequency of grade 3-4 hyperbilirubinemia (66.9% versus 50.4%, P = 0.006) and hypertriglyceridaemia (6.8% versus 1.5%, P = 0.031) occurred with dual therapy, although this never led to treatment discontinuation. A significant improvement in renal function and lumbar spine bone mineral density occurred in the dual-therapy arm. The evolution of CD4, HIV-DNA levels and neurocognitive performance was similar in both arms. Conclusions: In this randomized study, a treatment switch to atazanavir/ritonavir + lamivudine was superior over the continuation of atazanavir/ritonavir + 2NRTI in virologically suppressed patients, with a sustained benefit in terms of improved renal function and bone mineral density.
21
Updated research nosology for HIV-associated neurocognitive disorders
Andrea Antinori, Gabriele Arendt, James T. Becker et al. · Neurology · 2007 · 2.6K citations
Medicine, Neurology, Neuroscience +14
Anne‐Marie Taburet, Christophe Piketty, Corine Chazallon et al. · Antimicrobial Agents and Chemotherapy · 2004 · 211 citations · Full text
Recommendations for Evaluation and Management of Bone Disease in HIV
Todd T. Brown, Jennifer Hoy, Marco Borderi et al. · Clinical Infectious Diseases · 2015 · 183 citations · Full text
David A. Wohl, Shinichi Oka, Nathan Clumeck et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2016 · 179 citations · Full text